DiaMedica Therapeutics (DMAC) Change in Accured Expenses (2018 - 2026)

DiaMedica Therapeutics has reported Change in Accured Expenses for 9 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 6.46% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$807000.0 (down 169.87% YoY), and the FY2025 full-year result was -$892000.0, down 135.84% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.2 million, down from $282000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.3 million in Q4 2024, with the low at -$1.3 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $63588.2 across 5 years, with a median of $38000.0 in 2023.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses jumped 936.84% — and 2025, when it tumbled 7021.05%.
• DiaMedica Therapeutics' Change in Accured Expenses stood at $737000.0 in 2022, then decreased by 28.09% to $530000.0 in 2023, then surged by 145.47% to $1.3 million in 2024, then slumped by 78.32% to $282000.0 in 2025, then sank by 536.17% to -$1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.2 million (Q1 2026), $282000.0 (Q4 2025), and $469000.0 (Q3 2025), per Business Quant data.